EU marketing authorisation has been given to Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.
List view / Grid view
Research & Development (R&D)
Filter the results
A study has demonstrated in mice the success of a vaccine design which can be stored at room temperature for long periods of time.
A new report has shown a high level of novelty and diversity for the HIV first-in-class pipeline which targets drug resistance and latency reversal.
A new report has predicted that, even though the healthcare sector has been slow on the uptake, blockchain will play a pivotal role, creating new ways for pharmaceutical stakeholders to exchange information.
NICE has said it will not recommend gilteritinib for treatment of acute myeloid leukaemia (AML) due to uncertainty around long-term survival expectancy and its cost-effectiveness.
Ten priority actions have been recommended for the European medicines regulatory network to evolve its approach to data use.
Modified ‘super-human’ red blood cells containing therapeutic compounds have been developed by researchers as a novel form of drug delivery.
The first company to study cannabinol as an active pharmaceutical ingredient has launched its Phase I clinical trial.
A survey of industry professionals states they expect immuno-oncology therapies and personalised medicines to continue to shape the pharmaceutical industry in the coming year.
PQE GROUP, the international quality solution provider, at Interphex to consolidate its presence in US
PQE Group, the consulting company in the pharmaceutical field, based in Italy, has chosen “Interphex” to strengthen its presence on the US market.
The World Health Organization (WHO) has released new reports which state that a lack of innovation in new antibiotic development is undermining efforts to combat drug-resistant infections.
New research has found that the cell and gene therapy clinical environment in the UK has encouraged commercial sponsorship from around the world.
The US FDA has granted Fast Track Designation to APD418, which is in development as treatment for decompensated heart failure patients.